Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Universal Influenza Vaccine G1 mHA in Healthy Adults
NCT05901636Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2023
- Primary completion
- Aug 2024
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Influenza G1 mHA in influenza, sponsored by Janssen Pharmaceutical. Started May 2023; status: completed.
02
Drugs
Influenza G1 mHA
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05901636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05901636.